SEC Filing Summary: Zafgen, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Zafgen, Inc. on June 7, 2018, reporting events that occurred on June 6, 2018. The filing covers changes to the Board of Directors and the results of the Company's Annual Meeting of Stockholders. Note: The request metadata references "Larimar Therapeutics, Inc.," but the source text explicitly identifies the registrant as Zafgen, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and shareholder voting results rather than financial performance.
Material Changes
- Board Departures: Frances K. Heller resigned from the Board and Audit Committee. Bruce Booth, Ph.D., resigned from the Board. Both departures were due to retirement and were not the result of any disagreement with the Company.
- Board Election: Wendy Everett, Sc.D., was elected as a Class II director and appointed to the Audit Committee. She brings over 30 years of healthcare and health policy experience.
- Shareholder Voting: Stockholders approved the election of three Class I directors (Thomas O. Daniel, M.D., Cameron Geoffrey McDonough, M.D., and Robert J. Perez) and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, or specific risk factors. The document confirms that the departures of Ms. Heller and Dr. Booth were not related to disagreements regarding operations, policies, or practices.
Investor Verification Checklist
- Verify the identity of the registrant (Zafgen, Inc.) versus the metadata reference (Larimar Therapeutics, Inc.).
- Review the Definitive Proxy Statement filed on April 18, 2018, for detailed biographies of the newly elected directors.
- Confirm the total outstanding shares of common stock (27,563,346 as of April 11, 2018) for voting power calculations.
- Examine the press release (Exhibit 99.1) for additional context on the board changes.